Patents by Inventor Max Jan

Max Jan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230151342
    Abstract: The disclosure includes compositions comprising synthetic zinc finger degrons, and their use with non-naturally occurring or engineered programmable nucleases. Compositions specifically targeting the engineered programmable nucleases for control of gene editing outcomes, and compositions, systems and method of use are further detailed.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 18, 2023
    Inventors: Amit CHOUDHARY, Donghyun LIM, Sreekanth VEDAGOPURAM, Benjamin EBERT, Max JAN
  • Publication number: 20220098251
    Abstract: Described herein are compositions and methods for modulating protein abundance in a target-specific manner via degron tags.
    Type: Application
    Filed: December 18, 2019
    Publication date: March 31, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Eric Fischer, Benjamin L. Ebert, Max Jan, Radoslaw Nowak
  • Publication number: 20210040166
    Abstract: The present disclosure relates to therapeutic methods and clinically useful molecular switches, for which activity or degradation of a switch-presenting polypeptide can be precisely induced via administration or withdrawal of an FDA-approved drug. Certain aspects of the disclosure relate to an engineered drug-inducible heterodimeric system including a first polypeptide presenting a CRBN polypeptide disrupted for or lacking a DDB1-interacting domain and a second polypeptide presenting a CRBN polypeptide substrate, where binding between the CRBN polypeptide and the CRBN polypeptide substrate are inducible via administration of an FDA-approved thalidomide analog immunomodulatory drug (IMiD). Another aspect of the disclosure relates to a chimeric antigen receptor (CAR) that presents a minimal fragment of the CRBN polypeptide substrate IKZF3 capable of triggering proteasomal degradation of CAR upon administration of an FDA-approved IMiD.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 11, 2021
    Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM & WOMEN'S HOSPITAL, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Max Jan, Quinlan L. Sievers, Benjamin Ebert, Marcela Maus
  • Publication number: 20130183672
    Abstract: The invention relates to methods for determining the sequence of a genomic region of interest comprising a target nucleotide sequence comprising, fragmenting a crosslinked DNA, ligating the fragmented cross linked DNA, reversing the crosslinking and determining at least part of the sequences of ligated DNA fragments which comprise a target nucleotide sequence.
    Type: Application
    Filed: July 8, 2011
    Publication date: July 18, 2013
    Applicant: Cergentis B.V.
    Inventors: Wouter Leonard de Laat, Max Jan van Min
  • Publication number: 20120238457
    Abstract: The present invention relates to a method of ordering nucleic acid molecule fragment sequences derived from a pool of potentially diverse RNA molecules comprising optionally reverse transcribing the RNA molecules to provide a pool of cDNA molecules, segregating nucleic acids from said template RNA or cDNA pool, selecting for potentially different templates with a distinctive nucleic acid feature shared by the segregated templates, thereby providing at least a first subpool of nucleic acids, optionally once or more further segregating nucleic acids from said template RNA or cDNA, selectively segregating nucleic acids with a different distinctive nucleic acid feature, thereby providing one or more further subpool(s) of nucleic acids, generating fragments of said segregated nucleic acid molecules by fragmenting or obtaining fragment copies of said segregated nucleic acid molecules, wherein the fragments of each subpool or combined subpools remain separable from fragments of other subpools or other combined su
    Type: Application
    Filed: December 10, 2010
    Publication date: September 20, 2012
    Applicant: LEXOGEN GMBH
    Inventors: Alexander Seitz, Lukas Paul, Max Jan Van Min